CV
+3

Apr 15, 2026
•
16 min read
Muscle damage. Memory loss. Cancer. Diabetes. Four fears, one physician, and what the evidence actually shows.

CV
+3

Apr 11, 2026
•
12 min read
The receptor story that explains 40 years of cardiovascular outcomes data — and why the pleiotropic hypothesis was never the whole story.

GLP1
+2

Apr 8, 2026
•
14 min read
Six interventions. One thesis about time. What I take every morning and why the evidence earned each one a place in the rotation.

CV
+2

Apr 4, 2026
•
16 min read
Here's what the evidence actually says — and why I stopped waiting for symptoms before acting on it.

CV
+2

Apr 1, 2026
•
17 min read
New guidelines. New trials. The same conclusion. The deniers didn't get the memo.

GLP1
+3

Mar 27, 2026
•
15 min read
It's not the injection site. It's not gut GLP-1. It's not thermogenesis. The pharmacokinetics of semaglutide across multiple trials offer a surprisingly clean window into how this molecule — and this biology — actually works.

SUBSCRIBE TO MY NEWSLETTER